Investigational drug · Phase 2
AZD0292
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Bronchiectasis With Pseudomonas Aeruginosa Colonization.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "AZD0292"
First trial start
2025
Nov 6, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD0292", any sponsor or status.
Conditions studied
As listed on its trial records.
- Bronchiectasis With Pseudomonas Aeruginosa Colonization
Approved drugs for the same conditions: Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD0292" as an intervention, largest first.
- A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa ColonizationPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07088926 · 435 participants (planned) · Start Nov 6, 2025 · Primary completion Dec 9, 2027
Drug: AZD0292 · For: Bronchiectasis With Pseudomonas Aeruginosa Colonization
Sites: Orange, California; San Francisco, California; Denver, Colorado · 186 sites in all
AstraZenecaAstraZeneca (AZN)
NCT07774403 · 84 participants (planned) · Start Jun 24, 2026 · Primary completion Jan 18, 2028
Drug: AZD0292 · For: Bronchiectasis With Pseudomonas Aeruginosa Colonization
Sites: Anyang, China; Beijing, China; Changsha, China · 40 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06311760 · 32 participants · Start Apr 9, 2024 · Primary completion Feb 20, 2025
Drug: AZD0292; Placebo · For: Healthy Participants Study
Sites: Baltimore, Maryland
AstraZenecaAstraZeneca (AZN)
NCT07222254 · 18 participants · Start Dec 12, 2025 · Primary completion Jul 30, 2026
Drug: AZD0292; Placebo · For: Healthy Participants
Sites: Sumida-ku, Japan
Newest research
PubMed records naming it or its code names, newest first.
- Translational and phase I evaluation of AZD0292, a novel, half-life extended anti-Pseudomonal Psl-PcrV bispecific monoclonal antibody.
L E, Riff C, DiGiandomenico A, et al. · J Infect Dis 2026
- Correction: B107-14 Azd0292, a Novel Investigational Fc-engineered Humanized Monoclonal Antibody for Bronchiectasis With Chronic Pseudomonas Aeruginosa Colonization: Results From a Randomized Phase I Study in Healthy Adults.
· Am J Respir Crit Care Med 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.